Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Pulse Biosciences, Inc.    PLSE

PULSE BIOSCIENCES, INC.

(PLSE)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector news

Pulse Biosciences : to Participate in the H.C. Wainwright Global Investment Conference

09/01/2020 | 04:07pm EST

Pulse Biosciences, Inc. (Nasdaq: PLSE) a novel bioelectric medicine company progressing Nano-Pulse Stimulation™ (NPS™) technology, today announced plans to virtually participate in the upcoming H.C. Wainwright Global Investment Conference.

Management is scheduled to present Tuesday, September 15, 2020 at 1:30pm ET. Interested parties may access a live and recorded webcast on the “Investors” section of the Company’s website at www.pulsebiosciences.com.

About Pulse Biosciences®
Pulse Biosciences is a novel bioelectric medicine company committed to health innovation that has the potential to improve and extend the lives of patients. If cleared, the CellFX® System will be the first commercial product to harness the distinctive advantages of the Company’s proprietary Nano-Pulse Stimulation™ (NPS™) technology to treat a variety of applications for which an optimal solution remains unfulfilled. Nano-Pulse Stimulation technology delivers nano-second pulses of electrical energy to non-thermally clear cells while sparing adjacent non-cellular tissue. Subject to regulatory approval, the initial commercial use of the CellFX System is expected to address a broad range of dermatologic conditions that share high demand among patients and practitioners for improved and durable aesthetic outcomes. Designed as a multi-application platform, the CellFX System is intended to offer customer value with a utilization-based revenue model across an expanding spectrum of clinical applications. To learn more please visit www.pulsebiosciences.com.

Pulse Biosciences, CellFX, Nano-Pulse Stimulation, NPS and the stylized logos are among the trademarks and/or registered trademarks of Pulse Biosciences, Inc. in the United States and other countries.

Caution: Pulse Biosciences’ CellFX System and Nano-Pulse Stimulation technology are for investigational use only.


© Business Wire 2020
All news about PULSE BIOSCIENCES, INC.
12/04PULSE BIOSCIENCES : Presents Update on Nano-Pulse Stimulation™ Technology ..
BU
11/11PULSE BIOSCIENCES : to Participate in Upcoming Investor Conferences
BU
11/09PULSE BIOSCIENCES : Management's Discussion and Analysis of Financial Condition ..
AQ
11/09PULSE BIOSCIENCES, INC. : Results of Operations and Financial Condition, Financi..
AQ
11/09PULSE BIOSCIENCES : Reports Third Quarter 2020 Financial Results
BU
10/28PULSE BIOSCIENCES : Schedules Third Quarter 2020 Financial Results Conference Ca..
BU
10/07PULSE BIOSCIENCES : Announces Presentation of Clinical Results Using Nano-Pulse ..
BU
10/01PULSE BIOSCIENCES : Announces FDA IDE Approval and Initiation of Sebaceous Hyper..
BU
09/29PULSE BIOSCIENCES : Announces Receipt of MDSAP Certification
BU
09/15PULSE BIOSCIENCES : Grants Equity Incentive Awards To New Employees
BU
More news
Financials (USD)
Sales 2020 - - -
Net income 2020 - - -
Net Debt 2020 - - -
P/E ratio 2020 -
Yield 2020 -
Capitalization 434 M 434 M -
Capi. / Sales 2020 -
Capi. / Sales 2021 167x
Nbr of Employees 82
Free-Float 51,8%
Chart PULSE BIOSCIENCES, INC.
Duration : Period :
Pulse Biosciences, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PULSE BIOSCIENCES, INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 1
Average target price 16,00 $
Last Close Price 17,14 $
Spread / Highest target -6,65%
Spread / Average Target -6,65%
Spread / Lowest Target -6,65%
Managers
NameTitle
Darrin R. Uecker President, Chief Executive Officer & Director
Robert W. Duggan Chairman
Edison Manuel Vice President-Operations
Sandra A. Gardiner CFO, Secretary, Treasurer & Executive VP-Finance
Richard Nuccitelli Chief Science Officer
Sector and Competitors